Contract Manufacturing in Pharmaceutical Industry, 2015-2025

Description:

Amongst the increasing financial pressures and the need to reduce cost and improve efficiencies, the pharmaceutical industry has witnessed a paradigm shift from vertically integrated business model to a network of suppliers. As such, contract manufacturing has evolved as one of the integral components of the pharmaceutical market. Started initially as a one-off activity, contract manufacturing has evolved into a dynamic business model; currently most prevalent in manufacturing, outsourcing is steadily spanning the entire pharmaceutical value chain. With CMOs now offering the entire multitude of services from design and discovery to final packaging, the concept of 'one stop shop' service provider is gradually gaining pace.

The market has witnessed several major trends that have governed the evolution of contract manufacturing over the past few years. One of the most significant changes in the outsourcing space is the emergence of strategic contract manufacturing. The conventional model of contract manufacturing involved a vendor-customer equation. However, phasing out that traditional concept, contract manufacturers nowadays believe in entering in strategic alliances with CMO partners with the objective of cutting down production cost and enhancing product pipelines.

The contract manufacturing market, broadly categorized into API manufacturing and FDF manufacturing, has witnessed significant growth in the past several years driven by factors such as cost efficiency, technical expertise, and increased time efficiency. The current marketplace is inundated with numerous established as well as emerging CMOs, with a diverse array of service offerings and scale of operation. Despite being faced with challenges such as heavy competition and lack of funding, contract manufacturing in itself characterizes a huge opportunity for the pharmaceutical sector. Inevitably, substantial growth prospects lie ahead for pharmaceutical contract manufacturers; CMOs who will be able to provide certain differentiating elements targeting diverse customer groups stand to benefit the most in this competitive landscape.

The "Contract Manufacturing in Pharmaceutical Industry, 2015 - 2025" report provides an extensive study of the rapidly growing pharmaceutical contract manufacturing market. With pharmaceutical and biotechnology industry striving to minimize costs and maximize profits, outsourcing has emerged as an ever increasing trend. The study presents an in-depth analysis of a diverse set of CMOs on some of the key parameters such as type of business operation, scale of operation, packaging form, geographical location and range of services. In addition, it captures some of the key growth areas which will likely present tremendous opportunities for CMOs and ensure an accelerated pace of growth. Some of the potential growth areas include biopharmaceutical and high potency manufacturing. Specifically, in these markets, complex manufacturing requirements and capital intensive nature of the business make outsourcing an attractive option.

The report assesses some of the key drivers that have governed the evolution of contract manufacturing market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity in the pharmaceutical contract manufacturing market over the next decade, segmented on the basis of business operations and key regions.

In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples include quality concerns, cultural differences and lack of transparency in the manufacturing process. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run.

The base year for the report is 2014; the report provides market forecasts for the period 2015 - 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Contents:

1. Preface
   1.1. Scope of the Report
   1.2. Research Methodology
6.2. Analysis by Business Operations
6.3. Analysis by Scale of Operations
6.4. Analysis by Type of FDF
6.5. Analysis by Pharma Form Packaging
6.6. Analysis by Services
6.7. Analysis by Geography

7. Biopharmaceutical Contract Manufacturing
7.1. Chapter Overview
7.2. Manufacturing of Biopharmaceuticals
7.2.1. Microbial Expression Systems
7.2.1.1. Bacterial Protein Expression System
7.2.1.2. Yeast Protein Expression System
7.2.2. Mammalian Protein Expression System
7.2.3. Insect Protein Expression System
7.2.4. Plant Protein Expression System
7.3. Evolution of Biopharmaceutical Contract Manufacturing
7.4. Biopharmaceutical CMOs: Analysis by Region
7.5. Biopharmaceutical CMOs: Analysis by Scale of Operation
7.6. Biopharmaceutical CMOs: Analysis by Capability
7.6.1. Distribution by Type of Biologic Molecule
7.6.2. Distribution by Expression Systems
7.7. Biopharmaceutical CMOs: Type of Bioreactor

8. Market Size and Forecast
8.1. Forecast Methodology
8.2. Key Drivers
8.3. API Manufacturing Market, 2014 - 2025
8.4. FDF Contract Manufacturing Market, 2014 - 2025
8.4.1. FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
8.5. Overall Contract Manufacturing Market, 2014 - 2025
8.6. Contract Manufacturing Market: Regional View

9. Company Profiles
9.1. Chapter Overview
9.2. Patheon
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Manufacturing Capabilities
9.2.3.1. Manufacturing Locations
9.2.3.2. Technical Solutions
9.2.4. Partnerships
9.2.5. Approvals
9.2.6. Expansions
9.2.7. Future Outlook
9.3. Catalent
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Manufacturing Capabilities
9.3.3.1. Manufacturing Locations
9.3.3.2. Technical Solutions
9.3.4. Partnerships
9.3.5. Approvals
9.3.6. Expansions
9.3.6.1. Geographical Expansions
9.3.6.2. Capability Expansions
9.3.6.3. Capacity Expansions
9.3.7. Future Outlook
9.4. Fareva
9.4.1. Company Overview
9.4.2. Manufacturing Capabilities
9.4.2.1. Manufacturing Locations
9.4.3. Partnerships
9.4.4. Approvals
9.4.5. Expansions
9.4.5.1. Geographical Expansions
9.4.5.2. Capability Expansions
9.4.5.3. Capacity Expansions
9.4.6. Future Outlook
9.4.7. Excella GmbH, a Part of Fareva
9.5. Aenova
9.5.1. Company Overview
9.5.2. Manufacturing Capabilities
9.5.2.1. Dosage Forms
9.5.2.2. Manufacturing Locations
9.5.3. Approvals
9.5.4. Expansions
9.5.4.1. Geographic Expansions
9.5.4.2. Capability Expansions
9.5.4.3. Capacity Expansions
9.5.5. Future Outlook
9.5.6. Haupt Pharma
9.6. Lonza
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Manufacturing Capabilities
9.6.3.1. Manufacturing Locations
9.6.3.2. Technical Solutions
9.6.4. Partnerships
9.6.5. Expansions
9.6.5.1. Capability Expansions
9.6.5.2. Capacity Expansions
9.6.6. Future Outlook
9.7. Evonik
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Manufacturing Capabilities
9.7.3.1. Manufacturing Locations
9.7.4. Expansions
9.7.4.1. Geographic Expansions
9.7.4.2. Capability Expansions
9.7.4.3. Capacity Expansion
9.7.5. Future Outlook
9.8. Boehringer Ingelheim BioXcellence
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Manufacturing Capabilities
9.8.3.1. Manufacturing Locations
9.8.4. Partnerships
9.8.5. Expansions
9.8.5.1. Geographical Expansions
9.8.5.2. Capacity Expansions
9.8.6. Future Outlook
9.9. Aesica
9.9.1. Company Overview
9.9.2. Manufacturing Capabilities
9.9.2.1. Manufacturing Locations
9.9.2.2. Technical Solutions
9.9.3. Partnerships
9.9.4. Approvals
9.9.5. Expansions
9.9.5.1. Geographical Expansions
9.9.5.2. Capability Expansions
9.9.5.3. Capacity Expansions
9.9.6. Future Outlook
9.10. Famar
9.10.1. Company Overview
9.10.2. Manufacturing Capabilities
9.10.2.1. Manufacturing Locations
9.10.3. Partnerships
9.10.4. Expansions
9.10.4.1. Capacity Expansions
9.10.5. Future Outlook
9.11. Recipharm
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Manufacturing Capabilities
9.11.3.1. Manufacturing Locations
9.11.4. Partnerships
9.11.5. Approvals
9.11.6. Expansions
9.11.6.1. Geographical Expansions
9.11.6.2. Capability Expansions
9.11.6.3. Capacity Expansion
9.11.7. Future Outlook
9.12. Jubilant
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Manufacturing Capabilities
9.12.3.1. Manufacturing Locations
9.12.4. Partnerships
9.12.5. Future Outlook

10. Future of the CMO Market
10.1. Chapter Overview
10.2. Focus on Emerging Markets
10.3. Shift Towards an Integrated Business Model
10.4. Biologics to Expand the Global CMO Market
10.5. Innovation to Drive Growth
10.6. Information Sharing and Collaboration
10.7. High Potency and Cytotoxic Drugs Manufacturing: Emerging Focus
10.8. Growing Demand to Spur Investment Activity
10.9. Case Study: Contract Manufacturing in Gene Therapy

11. Interview Transcripts
11.1. Kevin Daley, Market Director (Pharmaceuticals), Novasep Synthesis
11.2. Roberto Margarita, Business Development Director, Corden Pharma
11.3. Allison Vavala, Senior Manager (Business Development), Helsinn
11.4. Bhaskar Venepalli, President and CEO, CiVentiChem

12. Conclusion
12.2. The Competitive Market to Witness an Accelerated Growth
12.3. Differentiation Strategy to Pave Way for Sustenance in the Market
12.4. Concluding Remarks

13. Appendix 1: Tabulated Data

14. Appendix 2: List Of Companies

List of Tables:
Table 5.1 Asymchem Laboratories: Manufacturing Facilities
Table 5.2 Porton Fine Chemicals: Manufacturing Facilities and R&D Centers
Table 5.3 Venturepharm Laboratories: Holdings and Related Companies
Table 5.4 Dr. Reddy's Laboratories: Manufacturing Facilities
Table 5.5 Dishman Pharma: Business Units
Table 6.1 CMOs: Analysis by Business Operations
Table 6.2 CMOs: Analysis by Scale of Operation
Table 6.3 CMOs: Analysis by Type of FDF
Table 6.4 CMOs: Analysis by Packaging Forms  
Table 6.5 CMOs: Range of Services  
Table 7.1 Biopharmaceutical CMOs: Scale of Operation  
Table 7.2 Biopharmaceutical CMOs: Type of Biologics  
Table 7.3 Biopharmaceutical CMOs: Analysis by Expression Systems  
Table 7.4 Biopharmaceutical CMOs: Analysis by Type of Bioreactor  
Table 9.1 Patheon: Capacity for Sterile Formulations Filling  
Table 9.2 Patheon: Facilities  
Table 9.3 Patheon: Additional Agreements, 2012-2014  
Table 9.4 Catalent: Manufacturing and Laboratory Facilities  
Table 9.5 Fareva: Manufacturing and Laboratory Facilities  
Table 9.6 Aenova: Manufacturing Locations  
Table 9.7 Lonza: Custom Development and Custom Manufacturing Sites  
Table 9.8 Evonik: Facilities Sites and their Functions  
Table 9.9 BioXcellence: Facilities and their Functions  
Table 9.10 Aesica: Facility Sites and their Functions  
Table 9.11 Famar: Facility Sites and their Functions  
Table 9.12 Recipharm: Facility sites and their Functions  
Table 9.13 Jubilant: Facility sites and their functions  
Table 10.1 HPAPI CMO Investments, 2006-2014  
Table 10.2 Contract Manufactures in Gene Therapy  
Table 13.1 Extent of Outsourcing in Pharmaceutical Operations  
Table 13.2 CMOs: Analysis by Business Operation, Scale and Type of FDF  
Table 13.3 CMOs: Distribution by Business Operations  
Table 13.4 CMOs: Distribution by Scale of Operation  
Table 13.5 CMOs: Distribution by FDF Dosage Forms  
Table 13.6 CMOs: Analysis by Packaging Form  
Table 13.7 CMOs: Distribution by Packaging Form  
Table 13.8 CMOs: Range of Services  
Table 13.9 CMOs: Regional distribution  
Table 13.10 Biopharmaceutical CMOs: Regional Distribution  
Table 13.11 Biopharmaceutical CMOs: Distribution by Scale of Operation  
Table 13.12 Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule  
Table 13.13 Biopharmaceutical CMOs: Distribution by Expression Systems  
Table 13.14 Biopharmaceutical CMOs: Analysis by Type of Bioreactor  
Table 13.15 Extent of Outsourcing: API and FDF Manufacturing, 2014 - 2025  
Table 13.16 API Manufacturing Market, 2014 - 2025: Base Scenario (USD Billion)  
Table 13.17 API Manufacturing Market, 2014 - 2025: Conservative Scenario (USD Billion)  
Table 13.18 API Manufacturing Market, 2014 - 2025: Optimistic Scenario (USD Billion)  
Table 13.19 FDF Manufacturing Market, 2014 - 2025: Base Scenario (USD Billion)  
Table 13.20 FDF Manufacturing Market, 2014 - 2025: Conservative Scenario (USD Billion)  
Table 13.21 FDF Manufacturing Market, 2014 - 2025: Optimistic Scenario (USD Billion)  
Table 13.22 FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025  
Table 13.23 Overall Contract Manufacturing Market, 2014 - 2025: Base Scenario (USD Billion)  
Table 13.24 Overall Contract Manufacturing Market, 2014 - 2025: Conservative Scenario (USD Billion)  
Table 13.25 Overall Contract Manufacturing Market, 2014 - 2025: Optimistic Scenario (USD Billion)  
Table 13.26 Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2025  
Table 13.27 Patheon: Revenues, 2009 - 2013 (USD million)  
Table 13.28 Patheon: Revenues by Business Divisions, 2013 (USD million)  
Table 13.29 Patheon: CMO Revenue Distribution, 2013 (USD million)  
Table 13.30 Catalent: Revenues, 2010 - 2014 (CHF million)  
Table 13.31 Catalent: Revenues by Business Divisions, 2014 (USD million)  
Table 13.32 Lonza: Revenues, 2010 - 2014 (CHF million)  
Table 13.33 Lonza: Revenues by Business Divisions, 2014 (CHF million)  
Table 13.34 Evonik: Revenues, 2009 - 2013 (EUR million)  
Table 13.35 Evonik: Revenues by Business Divisions, 2013 (EUR million)  
Table 13.36 Boehringer Ingelheim: Revenues, 2009 - 2013 (EUR million)  
Table 13.37 Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)  
Table 13.38 Recipharm: Revenues, 2009 - 2013 (SEK million)  
Table 13.39 Recipharm: Revenues by Business Divisions, 2013 (SEK million)  
Table 13.40 Jubilant: Revenues by Business Divisions, 2013 (INR million)  
Table 13.41 Contract Manufacturing in Gene Therapy: By Capability  
Table 13.42 Contract Manufacturing in Gene Therapy: By Location
List of Figures:
Figure 2.1 Range of Contract Manufacturing Services: Example CMOs
Figure 3.1 Roles of a Third Party Service Provider in Pharmaceutical Industry
Figure 3.2 Outsourcing across the Pharmaceutical Value Chain
Figure 3.3 CMOs: Range of Services
Figure 5.1 Chinese CMO Market: Growth Drivers
Figure 5.2 Indian CMO Market: Growth Drivers
Figure 6.1 Extent of Outsourcing in Pharmaceutical Operations
Figure 6.2 Pharmaceutical Contract Manufacturing Landscape
Figure 6.3 CMOs: Distribution by Business Operations
Figure 6.4 CMOs: Distribution by Scale of Operation
Figure 6.5 CMOs: Distribution by Type of Dosage Forms
Figure 6.6 Types of Pharmaceutical Packaging Forms
Figure 6.7 CMOs: Distribution by Packaging Form
Figure 6.8 CMOs: Regional Distribution
Figure 7.1 Types of Expression Systems
Figure 7.2 Biopharmaceutical CMOs: Geographical Location
Figure 7.3 Biopharmaceutical CMOs: Regional Distribution
Figure 7.4 Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 7.5 Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Figure 7.6 Biopharmaceutical CMOs: Distribution by Expression Systems
Figure 7.7 Single Use Bioreactors: Advantages and Disadvantages
Figure 8.1 Extent of Outsourcing: API and FDF Manufacturing, 2014 - 2025
Figure 8.2 API Manufacturing Market, 2014 - 2025: Base Scenario (USD billion)
Figure 8.3 FDF Manufacturing Market, 2014 - 2025: Base Scenario (USD billion)
Figure 8.4 FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
Figure 8.5 Overall Contract Manufacturing Market, 2014 - 2025: Base Scenario (USD billion)
Figure 8.6 Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2025
Figure 9.1 Patheon: Revenues, 2009 - 2013 (USD million)
Figure 9.2 Patheon: Revenues by Business Divisions, 2013 (USD million)
Figure 9.3 Patheon: Revenue Break-up for CMO, 2013 (USD million, Percentage)
Figure 9.4 Catalent: Revenues, 2010 - 2014 (USD million)
Figure 9.5 Catalent: Revenues by Business Divisions, 2014 (USD million)
Figure 9.6 Lonza: Revenues, 2010 - 2014 (USD million)
Figure 9.7 Lonza: Revenues by Business Divisions, FY 2014 (CHF million)
Figure 9.8 Lonza: Potency Classification System
Figure 9.9 Evonik: Revenues, 2009 - 2013 (USD million)
Figure 9.10 Evonik: Revenues by Business Divisions, 2013 (EUR million)
Figure 9.11 Boehringer Ingelheim: Revenues, 2009 - 2013 (EUR million)
Figure 9.12 Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)
Figure 9.13 Recipharm: Revenues, 2009 - 2013 (SEK million)
Figure 9.14 Recipharm: Revenues by Business Divisions, 2013 (SEK million)
Figure 9.15 Jubilant: Revenues by Business Divisions, FY 2014 (INR million)
Figure 10.1 Contract Manufacturing in Gene Therapy: By Capability
Figure 10.2 Contract Manufacturing in Gene Therapy: By Location
Figure 12.1 Pharmaceutical Contract Manufacturing: Key Drivers
Figure 12.2 API and FDF Contract Manufacturing Market (USD billion) Forecast: 2015, 2020 and 2024

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3113218/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Contract Manufacturing in Pharmaceutical Industry, 2015-2025
Web Address: http://www.researchandmarkets.com/reports/3113218/
Office Code: SCBR370E

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 2199</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 4999</td>
</tr>
<tr>
<td>Site License</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 8999</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐
First Name: __________________________  Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World